Healthcare company Organon (NYSE:OGN) said on Monday that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD).
The transaction is subject to Hart-Scott-Rodino review and US Food and Drug Administration (FDA) approval of alternate supply chain entities.
MIUDELLA, the first hormone-free copper IUD approved in the United States in 40 years, received FDA approval in February 2025 for up to three years of pregnancy prevention but is not yet commercially available. The device features a flexible frame and a preloaded inserter with a 3.7mm tapered insertion tube.
Under the deal, Organon will pay USD27.5m at closing, with potential sales-based milestone payments of up to USD505m and tiered double-digit royalties on net sales.
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
Hansa's imlifidase Biologics License Application accepted by FDA
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
Cambridge Cognition expands into India through Ivory commercialisation agreement
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
BillionToOne launches two new add-on liquid biopsy applications for Northstar Select